Literature DB >> 22926955

Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.

Xiaoyu Yan1, Yang Chen, Wojciech Krzyzanski.   

Abstract

The target-mediated drug disposition (TMDD) model has been adopted to describe pharmacokinetics for two drugs competing for the same receptor. A rapid binding assumption introduces total receptor and total drug concentrations while free drug concentrations C (A) and C (B) are calculated from the equilibrium (Gaddum) equations. The Gaddum equations are polynomials in C (A) and C (B) of second degree that have explicit solutions involving complex numbers. The aim of this study was to develop numerical methods to solve the rapid binding TMDD model for two drugs competing for the same receptor that can be implemented in pharmacokinetic software. Algebra, calculus, and computer simulations were used to develop algorithms and investigate properties of solutions to the TMDD model with two drugs competitively binding to the same receptor. A general rapid binding approximation of the TMDD model for two drugs competing for the same receptor has been proposed. The explicit solutions to the equilibrium equations employ complex numbers, which cannot be easily solved by pharmacokinetic software. Numerical bisection algorithm and differential representation were developed to solve the system instead of obtaining an explicit solution. The numerical solutions were validated by MATLAB 7.2 solver for polynomial roots. The applicability of these algorithms was demonstrated by simulating concentration-time profiles resulting from exogenous and endogenous IgG competing for the neonatal Fc receptor (FcRn), and darbepoetin competing with endogenous erythropoietin for the erythropoietin receptor. These models were implemented in ADAPT 5 and Phoenix WinNonlin 6.0, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926955      PMCID: PMC4032368          DOI: 10.1007/s10928-012-9267-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  21 in total

1.  Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

Authors:  Carlos Vaccaro; Jinchun Zhou; Raimund J Ober; E Sally Ward
Journal:  Nat Biotechnol       Date:  2005-09-25       Impact factor: 54.908

Review 2.  Lineage-specific hematopoietic growth factors.

Authors:  Kenneth Kaushansky
Journal:  N Engl J Med       Date:  2006-05-11       Impact factor: 91.245

3.  Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.

Authors:  Richard B Stead; John Lambert; Dawie Wessels; Julie S Iwashita; Kerstin K Leuther; Kathryn W Woodburn; Peter J Schatz; Douglas M Okamoto; Robert Naso; Anne-Marie Duliege
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

Review 4.  Target-mediated drug disposition and dynamics.

Authors:  Donald E Mager
Journal:  Biochem Pharmacol       Date:  2006-02-15       Impact factor: 5.858

5.  Approximations of the target-mediated drug disposition model and identifiability of model parameters.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Tarundeep Kakkar; Peiming Ma
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-13       Impact factor: 2.745

Review 6.  CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

Authors:  Iain C Macdougall
Journal:  Curr Hematol Rep       Date:  2005-11

7.  Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Authors:  Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-10       Impact factor: 2.745

8.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

Review 9.  FcRn: the neonatal Fc receptor comes of age.

Authors:  Derry C Roopenian; Shreeram Akilesh
Journal:  Nat Rev Immunol       Date:  2007-08-17       Impact factor: 53.106

10.  Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.410

View more
  17 in total

1.  Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.

Authors:  Anke-Katrin Volz; Andreas Krause; Walter Emil Haefeli; Jasper Dingemanse; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 2.  Assessment of non-linear combination effect terms for drug-drug interactions.

Authors:  Gilbert Koch; Johannes Schropp; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-16       Impact factor: 2.745

3.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Authors:  Wenbo Chen; Britton Boras; Tae Sung; Yanke Yu; Jenny Zheng; Diane Wang; Wenyue Hu; Mary E Spilker; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-03-11       Impact factor: 2.745

4.  Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.

Authors:  Gilbert Koch; William J Jusko; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-10       Impact factor: 2.745

5.  Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.

Authors:  Gilbert Koch; William J Jusko; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-10       Impact factor: 2.745

6.  New Equilibrium Models of Drug-Receptor Interactions Derived from Target-Mediated Drug Disposition.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  AAPS J       Date:  2018-05-14       Impact factor: 4.009

7.  Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; John Harrold
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-04       Impact factor: 2.745

8.  Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.

Authors:  Lene Alifrangis; Rik Schoemaker; Niels J Skartved; Rikke Hald; Clara Montagut; Scott Kopetz; Josep Tabernero; Michael Kragh; Janet R Wade
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-11-02       Impact factor: 2.745

9.  Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.

Authors:  Chee M Ng; Paul J Fielder; Jin Jin; Rong Deng
Journal:  AAPS J       Date:  2016-04-13       Impact factor: 4.009

10.  Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase.

Authors:  Nan Wu; Bruce D Hammock; Kin Sing Stephen Lee; Guohua An
Journal:  J Pharmacol Exp Ther       Date:  2020-04-01       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.